UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2019
OR
TRANSITION REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _______ to _______
COMMISSION FILE NUMBER 1-3619
----
PFIZER INC.
(Exact name of registrant as specified in its charter)
Delaware
13-5315170
(State of Incorporation)
(I.R.S. Employer Identification No.)
235 East 42nd Street, New York, New York 10017
(Address of principal executive offices) (zip code)
(212) 733-2323
(Registrant s telephone number)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $.05 par value
PFE
New York Stock Exchange
0.000% Notes due 2020
PFE20A
New York Stock Exchange
0.250% Notes due 2022
PFE22
New York Stock Exchange
1.000% Notes due 2027
PFE27
New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes
No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes
No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act:
Large Accelerated filer x Accelerated filer Non-accelerated filer Smaller reporting company Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes
No
At August 5, 2019, 5,531,048,353 shares of the issuer s voting common stock were outstanding.
Table of Contents
PART I. FINANCIAL INFORMATION
Page
Item 1.
Financial Statements
Condensed Consolidated Statements of Income for the three and six months ended June 30, 2019 and July 1, 2018
Condensed Consolidated Statements of Comprehensive Income for the three and six months ended June 30, 2019 and
July 1, 2018
Condensed Consolidated Balance Sheets as of June 30, 2019 and December 31, 2018
Condensed Consolidated Statements of Equity for the three and six months ended June 30, 2019 and July 1, 2018
Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2019 and July 1, 2018
10
Notes to Condensed Consolidated Financial Statements
11
Review Report of Independent Registered Public Accounting Firm
46
Item 2.
Management s Discussion and Analysis of Financial Condition and Results of Operations
47
Item 3.
Quantitative and Qualitative Disclosures About Market Risk
107
Item 4.
Controls and Procedures
107
PART II. OTHER INFORMATION
Item 1.
Legal Proceedings
108
Item 1A.
Risk Factors
108
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
109
Item 3.
Defaults Upon Senior Securities
109
Item 4.
Mine Safety Disclosures
109
Item 5.
Other Information
109
Item 6.
Exhibits
110
Signature
111
GLOSSARY OF DEFINED TERMS
Unless the context requires otherwise, references to Pfizer, the Company, we, us or our in this Quarterly Report on Form 10-Q (defined below) refer to Pfizer Inc. and its subsidiaries. We also have used several other terms in this Quarterly Report on Form 10-Q, most of which are explained or defined below:
2018 Financial Report
Financial Report for the fiscal year ended December 31, 2018, which was filed as Exhibit 13 to the Annual Report on Form 10-K for the fiscal year ended December 31, 2018
2018 Form 10-K
Annual Report on Form 10-K for the fiscal year ended December 31, 2018
ACA (Also referred to as U.S. Healthcare Legislation)
U.S. Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act
ACIP
Advisory Committee on Immunization Practices
ALK
anaplastic lymphoma kinase
Alliance revenues
Revenues from alliance agreements under which we co-promote products discovered or developed by other companies or us
Allogene
Allogene Therapeutics, Inc.
Anacor
Anacor Pharmaceuticals, Inc.
AOCI
Accumulated Other Comprehensive Income
Array
Array BioPharma Inc.
Astellas
Astellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc.
Bamboo
Bamboo Therapeutics, Inc.
Biopharma
Pfizer Biopharmaceuticals Group
BMS
Bristol-Myers Squibb Company
BRCA
BReast CAncer susceptibility gene
CAR T
chimeric antigen receptor T cell
CDC
U.S. Centers for Disease Control and Prevention
cGMP
current Good Manufacturing Practices
Citibank
Citibank, N.A.
Developed Markets
U.S., Western Europe, Japan, Canada, South Korea, Australia, Scandinavian countries, Finland and
New Zealand
EGFR
epidermal growth factor receptor
EH
Essential Health
EMA
European Medicines Agency
Emerging Markets
Includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea),
Latin America, Eastern Europe, the Middle East, Africa, Central Europe and Turkey
EPS
earnings per share
EU
European Union
Exchange Act
Securities Exchange Act of 1934, as amended
FASB
Financial Accounting Standards Board
FDA
U.S. Food and Drug Administration
GAAP
Generally Accepted Accounting Principles
GIST
gastrointestinal stromal tumors
GPD
Global Product Development organization
GSK
GlaxoSmithKline plc
GS&Co.
Goldman, Sachs & Co. LLC
hGH-CTP
human growth hormone
HIS
Hospira Infusion Systems
Hisun Pfizer
Hisun Pfizer Pharmaceuticals Company Limited
Hospira
Hospira, Inc.
HR+
hormone receptor-positive
ICU Medical
ICU Medical, Inc.
IH
Innovative Health
IPR&D
in-process research and development
IRS
U.S. Internal Revenue Service
IV
intravenous
Janssen
Janssen Biotech Inc.
J&J
Johnson & Johnson
King
King Pharmaceuticals LLC (formerly King Pharmaceuticals, Inc.)
LDL
low density lipoprotein
LEP
Legacy Established Products
LIBOR
London Interbank Offered Rate
Lilly
Eli Lilly & Company
LOE
loss of exclusivity
MCC
Merkel cell carcinoma
MCO
managed care organization
mCRC
metastatic colorectal cancer
MD&A
Management s Discussion and Analysis of Financial Condition and Results of Operations
Medivation
Medivation LLC (formerly Medivation, Inc.)
Merck
Merck & Co., Inc.
Meridian
Meridian Medical Technologies, Inc.
Moody s
Moody s Investors Service
Mylan
Mylan N.V.
NDA
new drug application
NSCLC
non-small cell lung cancer
NYSE
New York Stock Exchange
OPKO
OPKO Health, Inc.
OTC
over-the-counter
PARP
poly ADP ribose polymerase
PBM
pharmacy benefit manager
Pharmacia
Pharmacia Corporation
PP&E
property, plant & equipment
PsA
psoriatic arthritis
Quarterly Report on Form 10-Q
Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2019
RA
rheumatoid arthritis
RCC
renal cell carcinoma
R&D
research and development
ROU
right of use
Sandoz
Sandoz, Inc., a division of Novartis AG
SEC
U.S. Securities and Exchange Commission
SFJ
SFJ Pharmaceuticals Group
Shire
Shire International GmbH
SI&A
selling, informational and administrative
S&P
Standard and Poor s
TCJA
legislation commonly referred to as the U.S. Tax Cuts and Jobs Act of 2017
Therachon
Therachon Holding AG
UC
ulcerative colitis
U.K.
United Kingdom
U.S.
United States
ViiV
ViiV Healthcare Limited
WRDM
Worldwide Research, Development and Medical
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED)
Three Months Ended
Six Months Ended
(MILLIONS, EXCEPT PER COMMON SHARE DATA)
June 30,
2019
July 1,
2018
June 30,
2019
July 1,
2018
Revenues
13,264
13,466
26,382
26,373
Costs and expenses:
Cost of sales(a)
2,576
2,916
5,009
5,479
Selling, informational and administrative expenses(a)
3,511
3,542
6,850
6,954
Research and development expenses(a)
1,842
1,797
3,544
3,540
Amortization of intangible assets
1,184
1,191
2,367
2,387
Restructuring charges and certain acquisition-related costs
(115
44
(69
87
Other (income)/deductions net
126
(551
218
(728
Income from continuing operations before provision/(benefit) for taxes on income
4,141
4,527
8,463
8,654
Provision/(benefit) for taxes on income
(915
648
(481
1,204
Income from continuing operations
5,056
3,879
8,945
7,450
Discontinued operations net of tax
(1
Net income before allocation to noncontrolling interests
5,056
3,879
8,945
7,449
Less: Net income attributable to noncontrolling interests
10
15
16
Net income attributable to Pfizer Inc.
5,046
3,872
8,929
7,432
Earnings per common share basic:
Income from continuing operations attributable to Pfizer Inc. common shareholders
0.91
0.66
1.59
1.26
Discontinued operations net of tax
Net income attributable to Pfizer Inc. common shareholders
0.91
0.66
1.59
1.26
Earnings per common share diluted:
Income from continuing operations attributable to Pfizer Inc. common shareholders
0.89
0.65
1.56
1.24
Discontinued operations net of tax
Net income attributable to Pfizer Inc. common shareholders
0.89
0.65
1.56
1.24
Weighted-average shares basic
5,562
5,866
5,598
5,911
Weighted-average shares diluted
5,672
5,952
5,711
6,004
(a)
Excludes amortization of intangible assets, except as disclosed in Note 9A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.
Amounts may not add due to rounding.
See Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(UNAUDITED)
Three Months Ended
Six Months Ended
(MILLIONS OF DOLLARS)
June 30,
2019
July 1,
2018
June 30,
2019
July 1,
2018
Net income before allocation to noncontrolling interests
5,056
3,879
8,945
7,449
Foreign currency translation adjustments, net
(485
(699
(161
59
Reclassification adjustments
(35
(20
(485
(734
(159
39
Unrealized holding gains/(losses) on derivative financial instruments, net
(176
127
91
13
Reclassification adjustments for (gains)/losses included in net income(a)
(81
310
(343
354
(256
437
(252
367
Unrealized holding gains/(losses) on available-for-sale securities, net
(7
(374
33
(214
Reclassification adjustments for (gains)/losses included in net income(a)
26
143
37
(31
Reclassification adjustments for unrealized gains included in Retained earnings(b)
(462
19
(231
70
(707
Benefit plans: actuarial gains/(losses), net
(4
(57
(4
106
Reclassification adjustments related to amortization
60
61
121
123
Reclassification adjustments related to settlements, net
30
67
Other
41
107
18
21
100
141
137
316
Benefit plans: prior service costs and other, net
(1
(1
Reclassification adjustments related to amortization of prior service costs and other, net
(46
(46
(93
(92
Reclassification adjustments related to curtailments of prior service costs and other, net
(7
(13
Other
(1
(46
(53
(92
(104
Other comprehensive loss, before tax
(669
(440
(296
(88
Tax provision/(benefit) on other comprehensive loss
(59
173
(34
605
Other comprehensive loss before allocation to noncontrolling interests
(610
(613
(262
(693
Comprehensive income before allocation to noncontrolling interests
4,446
3,266
8,683
6,755
Less: Comprehensive income/(loss) attributable to noncontrolling interests
12
(4
13
Comprehensive income attributable to Pfizer Inc.
4,434
3,270
8,669
6,750
(a)
Reclassified into Other (income)/deductions net and Cost of sales in the condensed consolidated statements of income. For additional information on amounts reclassified into Cost of sales, see Note 7E. Financial Instruments: Derivative Financial Instruments and Hedging Activities.
(b)
For additional information, see Notes to Consolidated Financial Statements Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2018 in our 2018 Financial Report.
Amounts may not add due to rounding.
See Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(MILLIONS OF DOLLARS)
June 30,
2019
December 31,
2018
(Unaudited)
Assets
Cash and cash equivalents
1,784
1,139
Short-term investments
11,128
17,694
Trade accounts receivable, less allowance for doubtful accounts: 2019 $540; 2018 $541
9,793
8,025
Inventories
8,233
7,508
Current tax assets
3,723
3,374
Other current assets
2,535
2,461
Assets held for sale
9,877
9,725
Total current assets
47,073
49,926
Long-term investments
2,905
2,767
Property, plant and equipment, less accumulated depreciation: 2019 $16,389; 2018 $16,591
13,521
13,385
Identifiable intangible assets, less accumulated amortization
33,024
35,211
Goodwill
53,352
53,411
Noncurrent deferred tax assets and other noncurrent tax assets
1,935
1,924
Other noncurrent assets
4,388
2,799
Total assets
156,199
159,422
Liabilities and Equity
Short-term borrowings, including current portion of long-term debt: 2019 $2,139; 2018 $4,776